Marc Miravitlles*,1, Kai-Michael Beeh2 & Pablo Altman3 Department of Pneumology, Hospital Universitari Vall d’Hebron, Ciber de Enfermedades Respiratorias (Ciberes), P. Vall d’Hebron 119–129, 08035, Barcelona, Spain Insaf Institut für Atemwegsforschung GmbH, Biebricher Allee 34, D-65187 Wiesbaden, Germany Novartis Pharmaceuticals Corporation, 1 Health Plz, East Hanover, NJ 07936, USA *Author for...

Dose after a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents Xavier Saez-Llorens, MD; Diana Catalina Aguilera Vaca, MD; Katia Abarca, MD; Emmanuelle Maho, MSc; Linda Han, MD; Igor Smolenov, MD; Peter Dull, MD; Hospital del Niño, Panama City, Panama; Centro de Investigacion, Colombia, Colombia; Pontificia Universidad Catolica de Chile, Santiago, Chil...

Disclosure of Potential Conflicts of Interest B. Paiva reports receiving speakers bureau honoraria from Becton, Dickinson and Company, Binding Site, Celgene, Janssen, and Millennium Pharmaceuticals. J.F. San Miguel is a consultant/advisory board member for Bristol-Myers Squibb, Celgene, Janssen, Merck, Millennium Pharmaceuticals, Novartis, and Onyx Pharmaceuticals. No potential conflicts of int...

Supported by: Main financial support for the MRC Myeloma IX clinical trial was from the UK Medical Research Council, with additional funding in the form of unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene and Ortho Biotech. The LLR UKMF Cytogenetics group was supported by Leukemia and Lymphoma Research. The Institute of Cancer Research received fina...

Lynsey Meikle,1 Kristen Pollizzi,1 Anna Egnor,1 Ioannis Kramvis,2 Heidi Lane,3 Mustafa Sahin,2 and David J. Kwiatkowski1 1Division of Translational Medicine, Department of Medicine, Brigham and Women’s Hospital and 2Department of Neurology, Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, and 3Novartis Institutes for BioMedical Research, Oncology Basel, Novartis Pharma ...

Funding Editorial support was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Conflict of interest: G.K.H.: none declared; M.H.D.: acted as consultant/advisory board member for Amgen, AstraZeneca, Merck, and Sanofi-Aventis and a stockholder in Omthera Pharmaceuticals, Inc.; J.J.P.K.: a consultant to Regeneron, Sanofi, Eli Lilly, Amgen, Aegerion, Merck, Isis, Genzyme, Novartis, Kowa; A.M.O....

The Symposium entitled 'Conceptual Knowledge: Developmental, Biological, Functional and Computational Accounts' was held at the British Academy, London, UK on 24-26 June 2002. It was funded by the British Academy with support from the Novartis Foundation, and organized by Lorraine Tyler (University of Cambridge, UK) and Tim Shallice (University College London, UK).

Laura H. Jacobson,1 Peter H. Kelly,1 Bernhard Bettler,2 Klemens Kaupmann,1 and John F. Cryan1,3 1Novartis Institutes for BioMedical Research, Novartis Pharma, CH-4002 Basel, Switzerland, 2Institute of Physiology, Department of Clinical-Biological Sciences, Pharmazentrum, University of Basel, CH-4056 Basel, Switzerland, and 3Department of Pharmacology and Therapeutics, School of Pharmacy, Univer...

Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Albert-Ludwigs-University, Freiburg, Germany; Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN; Genetics Laboratory, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany; Department of Pathology, Freibu...